Ignite Creation Date:
2024-05-05 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00019565
Status:
COMPLETED
Last Update Posted:
2016-09-26
First Post:
2001-07-11
Brief Title:
PET andor MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
Sponsor:
National Institutes of Health Clinical Center CC
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
The Use of Positron Emission Tomography PET and Magnetic Resonance Imaging MRI to Assess the Effects of Anti-neoplastic Therapy on Tumor Associated Vasculature
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Diagnostic procedures such as PET and MRI scans may help to measure a patients response to treatment
PURPOSE This diagnostic trial is studying how well PET andor MRI scans work in assessing changes in tumor blood supply in patients receiving antiangiogenesis therapy
PURPOSE This diagnostic trial is studying how well PET andor MRI scans work in assessing changes in tumor blood supply in patients receiving antiangiogenesis therapy
Detailed Description:
OBJECTIVES
Evaluate the ability of positron emission tomography PET to assess the effect of therapy directed against tumor vasculatures on tumor blood flow and tumor blood volume in patients enrolled on a treatment protocol evaluating a therapeutic modality effecting the tumor associated vasculature
Evaluate the ability of PET to assess the effects of this type of therapy regimen on tumor uptake of fluorodeoxyglucose in these patients
Evaluate the ability of magnetic resonance imaging MRI to assess the effects of therapy directed against the tumor vasculature on tumor blood flow and tumor vascular density in these patients
Compare the findings on PET andor MRI with those obtained from conventional CT in this patient population
OUTLINE This is a diagnostic study conducted concurrently with a therapeutic modality study
Patients have magnetic resonance imaging andor positron emission tomography PET scans performed prior to start of therapy 6 weeks and 16 weeks following the initiation of therapy and 6 weeks following the completion of therapy Each scan requires about 1-3 hours Patients receive up to 3 different PET scans including tumor blood flow scan with H2015 tumor blood volume scan with 11CO and glucose uptake scan with fludeoxyglucose F 18
PROJECTED ACCRUAL A total of 145 patients will be accrued for this study within 2 years
Evaluate the ability of positron emission tomography PET to assess the effect of therapy directed against tumor vasculatures on tumor blood flow and tumor blood volume in patients enrolled on a treatment protocol evaluating a therapeutic modality effecting the tumor associated vasculature
Evaluate the ability of PET to assess the effects of this type of therapy regimen on tumor uptake of fluorodeoxyglucose in these patients
Evaluate the ability of magnetic resonance imaging MRI to assess the effects of therapy directed against the tumor vasculature on tumor blood flow and tumor vascular density in these patients
Compare the findings on PET andor MRI with those obtained from conventional CT in this patient population
OUTLINE This is a diagnostic study conducted concurrently with a therapeutic modality study
Patients have magnetic resonance imaging andor positron emission tomography PET scans performed prior to start of therapy 6 weeks and 16 weeks following the initiation of therapy and 6 weeks following the completion of therapy Each scan requires about 1-3 hours Patients receive up to 3 different PET scans including tumor blood flow scan with H2015 tumor blood volume scan with 11CO and glucose uptake scan with fludeoxyglucose F 18
PROJECTED ACCRUAL A total of 145 patients will be accrued for this study within 2 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000066720 | None | None | None |
| 98-C-0163 | None | None | None |